Bradley L.  Campbell net worth and biography

Bradley Campbell Biography and Net Worth

Bradley Campbell is the president and chief executive officer at Amicus, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. He also serves on the company’s board of directors. He has held the president and COO roles since 2015.  In 2022 he accepted the CEO position.

Campbell joined the company in 2006 as senior director of business development, and he currently directs the global commercial organization in charge of the design, strategy and execution of the Galafold™ launch. Additionally, he presides over the market access, technical operations and program management functions of the business. Before joining Amicus, he held commercial and business development positions with Genzyme and Bristol-Myers Squibb, as well as serving as business strategy consultant with Marakon Associates.

In addition to his role with Amicus, Campbell is involved with numerous boards and other charitable groups. He currently sits on the board of ARYA Sciences Acquisition Corp III, the Association for Regenerative Medicine (ARM), BioNJ and the corporate advisory board for the National Tay-Sachs and Allied Diseases Association. He previously served on the board for Progenics Pharmaceuticals.

Campbell earned his bachelor’s degree in public policy at Duke University and his M.B.A. at Harvard Business School.

What is Bradley L. Campbell's net worth?

The estimated net worth of Bradley L. Campbell is at least $9.20 million as of July 5th, 2024. Mr. Campbell owns 886,654 shares of Amicus Therapeutics stock worth more than $9,203,469 as of July 22nd. This net worth approximation does not reflect any other assets that Mr. Campbell may own. Additionally, Mr. Campbell receives an annual salary of $984,090.00 as CEO at Amicus Therapeutics. Learn More about Bradley L. Campbell's net worth.

How old is Bradley L. Campbell?

Mr. Campbell is currently 48 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. Learn More on Bradley L. Campbell's age.

What is Bradley L. Campbell's salary?

As the CEO of Amicus Therapeutics, Inc., Mr. Campbell earns $984,090.00 per year. Learn More on Bradley L. Campbell's salary.

How do I contact Bradley L. Campbell?

The corporate mailing address for Mr. Campbell and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Bradley L. Campbell's contact information.

Has Bradley L. Campbell been buying or selling shares of Amicus Therapeutics?

During the last quarter, Bradley L. Campbell has sold $61,000.00 of Amicus Therapeutics stock. Most recently, Bradley L. Campbell sold 6,100 shares of the business's stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a transaction totalling $61,000.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at $8,866,540. Learn More on Bradley L. Campbell's trading history.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 33 times. They sold a total of 458,947 shares worth more than $5,962,328.23. The most recent insider tranaction occured on July, 5th when CEO Bradley L Campbell sold 6,100 shares worth more than $61,000.00. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.

Information on this page was last updated on 7/5/2024.

Bradley L. Campbell Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2024Sell6,100$10.00$61,000.00886,654View SEC Filing Icon  
5/1/2024Sell7,500$10.07$75,525.00886,654View SEC Filing Icon  
2/15/2024Sell4,167$14.00$58,338.00871,219View SEC Filing Icon  
1/2/2024Sell15,833$14.23$225,303.59947,805View SEC Filing Icon  
12/1/2023Sell11,702$11.08$129,658.16792,161View SEC Filing Icon  
11/1/2023Sell11,700$10.97$128,349.00792,161View SEC Filing Icon  
10/2/2023Sell11,700$11.24$131,508.00792,161View SEC Filing Icon  
9/1/2023Sell18,093$12.97$234,666.21792,161View SEC Filing Icon  
8/1/2023Sell20,000$13.39$267,800.00798,554View SEC Filing Icon  
7/12/2023Sell1,500$12.51$18,765.00813,654View SEC Filing Icon  
7/3/2023Sell11,700$12.31$144,027.00815,154View SEC Filing Icon  
6/6/2023Sell8,300$12.50$103,750.00815,154View SEC Filing Icon  
6/1/2023Sell11,700$11.36$132,912.00823,454View SEC Filing Icon  
5/1/2023Sell11,700$11.80$138,060.00823,454View SEC Filing Icon  
4/3/2023Sell11,700$11.21$131,157.00823,454View SEC Filing Icon  
2/1/2023Sell20,000$12.98$259,600.00845,129View SEC Filing Icon  
1/9/2023Sell11,700$11.43$133,731.00805,536View SEC Filing Icon  
12/1/2022Sell5,485$12.20$66,917.00689,618View SEC Filing Icon  
11/1/2022Sell5,470$10.01$54,754.70689,618View SEC Filing Icon  
10/3/2022Sell5,470$10.53$57,599.10689,618View SEC Filing Icon  
8/1/2022Sell5,470$10.03$54,864.10689,618View SEC Filing Icon  
7/1/2022Sell5,470$10.72$58,638.40689,618View SEC Filing Icon  
6/21/2022Sell16,410$10.00$164,100.00689,618View SEC Filing Icon  
3/18/2022Sell10,940$10.00$109,400.00View SEC Filing Icon  
1/3/2022Sell5,470$11.86$64,874.20View SEC Filing Icon  
12/22/2021Sell3,000$11.70$35,100.00View SEC Filing Icon  
12/1/2021Sell10,515$11.00$115,665.00View SEC Filing Icon  
11/1/2021Sell10,515$11.32$119,029.80View SEC Filing Icon  
10/1/2021Sell10,515$10.00$105,150.00View SEC Filing Icon  
9/1/2021Sell10,515$11.50$120,922.50View SEC Filing Icon  
8/5/2021Sell21,028$10.02$210,700.56View SEC Filing Icon  
6/7/2021Sell10,514$10.01$105,245.14436,397View SEC Filing Icon  
5/3/2021Sell10,514$10.27$107,978.78422,536View SEC Filing Icon  
4/1/2021Sell10,514$10.03$105,455.42389,371View SEC Filing Icon  
1/4/2021Sell10,514$22.17$233,095.38347,215View SEC Filing Icon  
12/1/2020Sell24,783$22.77$564,308.91363,547View SEC Filing Icon  
11/2/2020Sell24,782$17.87$442,854.34363,546View SEC Filing Icon  
9/28/2020Sell24,782$13.89$344,221.98363,546View SEC Filing Icon  
7/8/2020Sell2,500$16.01$40,025.00341,264View SEC Filing Icon  
7/1/2020Sell12,500$15.47$193,375.00351,264View SEC Filing Icon  
6/1/2020Sell17,502$12.66$221,575.32365,355View SEC Filing Icon  
5/26/2020Sell2,500$13.01$32,525.00357,855View SEC Filing Icon  
5/1/2020Sell17,503$11.33$198,308.99372,858View SEC Filing Icon  
4/7/2020Sell2,500$10.12$25,300.00365,358View SEC Filing Icon  
4/1/2020Sell15,003$9.09$136,377.27363,014View SEC Filing Icon  
3/5/2020Sell2,500$10.01$25,025.00358,014View SEC Filing Icon  
2/5/2020Sell2,500$10.01$25,025.00365,517View SEC Filing Icon  
2/3/2020Sell15,003$8.91$133,676.73378,020View SEC Filing Icon  
1/15/2020Sell5,064$10.35$52,412.40370,520View SEC Filing Icon  
1/9/2020Sell2,500$10.01$25,025.00347,695View SEC Filing Icon  
1/2/2020Sell22,127$9.58$211,976.66253,987View SEC Filing Icon  
1/22/2019Sell36,000$11.81$425,160.00275,360View SEC Filing Icon  
1/22/2018Sell32,500$15.92$517,400.00186,600View SEC Filing Icon  
3/2/2017Sell49,050$8.00$392,400.00127,475View SEC Filing Icon  
9/21/2015Sell13,001$16.78$218,156.78156,575View SEC Filing Icon  
6/19/2015Sell13,000$13.26$172,380.00View SEC Filing Icon  
11/25/2014Sell7,250$8.00$58,000.00View SEC Filing Icon  
8/25/2014Sell7,000$6.00$42,000.00View SEC Filing Icon  
8/20/2014Sell18,750$5.40$101,250.00View SEC Filing Icon  
See Full Table

Bradley L. Campbell Buying and Selling Activity at Amicus Therapeutics

This chart shows Bradley L Campbell's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $10.28
Low: $10.21
High: $10.61

50 Day Range

MA: $9.99
Low: $9.04
High: $10.84

2 Week Range

Now: $10.28
Low: $9.02
High: $14.57


3,069,428 shs

Average Volume

2,773,343 shs

Market Capitalization

$3.04 billion

P/E Ratio


Dividend Yield